Savara (SVRA) EBT Margin (2013 - 2020)

Savara (SVRA) posted quarterly EBT Margin of 248259200.0% for Q4 2020, down 5648171.88% quarter-over-quarter from 4395.31% in Q3 2020.

Savara (SVRA) EBT Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has reported EBT Margin for 5 consecutive years, with 248259200.0% the latest figure, recorded in Q4 2020.

In Q4 2020, EBT Margin changed N/A year-over-year to 248259200.0%; the TTM figure through Mar 2022 stood at 4041700.0% (changed N/A YoY), while the FY2020 annual figure was 980290.66%, changed N/A from the prior year.
EBT Margin eased to 248259200.0% in Q4 2020 per SVRA's latest filing, from 4395.31% in the prior quarter.
Across five years, EBT Margin topped out at 12738.3% in Q2 2017 and bottomed at 248259200.0% in Q4 2020.
Historically, EBT Margin has averaged 41377378.62% across 3 years, with a median of 4969.46% in 2017.
On a YoY basis, EBT Margin climbed as much as 2182037 bps in 2016 and fell as far as 2182037 bps in 2016.
Savara's EBT Margin stood at 700.0% in 2016, then surged by 1920 bps to 12738.3% in 2017, then plunged by 1949020 bps to 248259200.0% in 2020.
Business Quant data shows SVRA's EBT Margin at 248259200.0% in Q4 2020, 4395.31% in Q3 2020, and 12738.3% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data